Medical News

RSS

Dyadic second-quarter 2010 total revenue decreases to $2.2 million

Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of specialty enzyme products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced financial results for the second quarter ended June 30, 2010.

13 Aug 2010

KHN column: Medicaid rescissions worse than private insurers

On Tuesday, members of the House of Representatives interrupted their August vacation and returned to Washington to vote on a bill to send money to the states. The issue that dominated the news was saving the jobs of teachers, police officers and other public employees. But most of the money allocated will prevent the states from cutting off health benefits for millions of people.

13 Aug 2010

Nearly 1100 foodborne outbreaks reported nationally in 2007: CDC analysis

A total of 1,097 foodborne disease outbreaks were reported in 2007 to the Centers for Disease Control and Prevention, according to a CDC analysis. State investigators reported 21,244 illnesses and 18 deaths as a result of these outbreaks. The report also provides the most recent data on how many illnesses were linked to specific types of foods.

13 Aug 2010

ACAM, AAEM sign agreement to host joint conference in Portland

The American College for Advancement in Medicine and the American Academy of Environmental Medicine are excited to announce they have reached an agreement to host a joint conference and tradeshow, November 16 - 20, 2011 in Portland, Oregon.

13 Aug 2010

Quick-Med Technologies, Biosara sign development agreement

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has signed a development agreement with Biosara Corporation, a medical device company targeting wound dressings for major medical and healthcare providers, along with the multi-billion dollar organized sports athlete markets.

13 Aug 2010

Five tips for seniors researching MA or Medigap plan options

Health Plan One, a general agent in the online health insurance market, seeks to guide seniors to choose carefully when selecting their Medicare Advantage or Medicare supplement plan. Seniors will have only one opportunity to make changes to their Medicare plans during the Annual Enrollment Period this November 15 through December 31.

13 Aug 2010

Activists, care providers, patients protest against Senator Nelson's silence on AIDS drug program

While Florida continues to add up to 300 people each month to its waiting list for its AIDS Drug Assistance Program, scores of AIDS activists, care providers and patients will gather at a protest and press briefing hosted by AIDS Healthcare Foundation, Friday, August 13th at 12:00 Noon outside the Tampa offices of United States Senator Bill Nelson (D, FL).

13 Aug 2010

Canadian Red Cross ramps up relief efforts in flood ravaged Pakistan

The Canadian Red Cross is ramping up relief efforts in flood ravaged Pakistan. A Red Cross distribution planned for Sunday will put much-needed emergency supplies into the hands of 400 families in the SWAT valley. The supplies, funded by Canadian donations, will include tents, blankets and hygiene kits.

13 Aug 2010

Management of therapy-resistant schizophrenia

The psychotic symptoms of up to 30% of schizophrenic patients do not respond adequately to treatment with antipsychotic drugs, other than clozapine. These refractory patients are generally among the most disabled of all people with schizophrenia and require special assessment and treatment.

13 Aug 2010

PROFIT magazine ranks Prollenium as one of Canada's Fastest Growing Companies

Ario Khoshbin, President of Prollenium Medical Technologies Inc., a privately held specialty medical device company, reported today that his firm will continue to record strong year on year gains in revenues and profitability for its 2010 Fiscal Year ending June 30th. Over the past five years, Prollenium has recorded aggregate revenue growth of more than 524% ranking it amongst Canada's fastest growing firms.

13 Aug 2010

THN President applauds FTC, State enforcement officials for crackdown on insurance scammers

Betty Heiman, Founder and President of Transparent Health Network, praised the announcement made today that the FTC and State enforcement officials will crackdown on scammers who target uninsured, unemployed and uninsurable individuals by peddling fraudulent medical discount plans. These plans, according to government officials, are marketed as health insurance but possess few or none of the features either of insurance or of actual plans.

13 Aug 2010

U.S. FDA purchases more licenses to Simulations Plus' DDDPlus software

Simulations Plus, Inc., a leading provider of software for pharmaceutical discovery and development, today announced that it has received a purchase order from the U.S. Food and Drug Administration to expand the number of licenses for the Company's DDDPlus™ simulation software.

13 Aug 2010

SANUWAVE second-quarter revenues decrease to $117,000

SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, today reported financial results for the three and six months ended June 30, 2010 and provided a business update.

13 Aug 2010

Validare achieves national certification from ACCME for medical education program

Validare has been awarded national certification for their continuing medical education program. The training that Validare provides to physicians and their staff on how to become accredited for Office Based Surgery has now been recognized by the ACCME. Physicians who participate in Validare's accreditation preparation program will receive CME credits for the time they spend working on becoming accredited for office based surgery.

13 Aug 2010

Soligenix’s net loss for second-quarter 2010 decreases to $1,577,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the second quarter of 2010.

13 Aug 2010

LabCorp announces collaboration between Esoterix Clinical Trials Services, Clearstone Central Laboratories

Laboratory Corporation of America Holdings announced today a collaboration between Esoterix Clinical Trials Services, a division of LabCorp, and Clearstone Central Laboratories, a global central laboratory specializing in drug development and pharmaceutical services.

13 Aug 2010

CeNeRx BioPharma raises $13 million through Series C financing to support TriRima Phase II trial

CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $13 million Series C financing. Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners and Pappas Ventures all participated in the financing. CeNeRx plans to use the proceeds to conduct a Phase II trial of its improved formulation of its novel antidepressant TriRima™.

13 Aug 2010

Catalyst second-quarter net loss decreases to $1,328,541

Catalyst Pharmaceutical Partners, Inc. today announced its financial results for the second quarter and six months ended June 30, 2010.

13 Aug 2010

CRF announces additional featured trials to be presented at Transcatheter Cardiovascular Therapeutics 2010

The Cardiovascular Research Foundation has announced that in addition to the previously announced late breaking clinical trials and first reports, a series of additional featured trials will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium. These trials will focus on a wide range of significant topics in interventional cardiovascular medicine. TCT 2010 will take place September 21 - 25 in Washington, DC.

13 Aug 2010

Trubion Pharmaceuticals signs definitive merger agreement with Emergent BioSolutions

Trubion Pharmaceuticals, Inc. today announced the signing of a definitive merger agreement with Emergent BioSolutions Inc., in which Emergent has agreed to acquire Trubion. Under the terms of the agreement, each share of Trubion common stock will be converted into the right to receive an upfront payment of $1.365 per share in cash and 0.1641 shares of Emergent BioSolutions common stock.

13 Aug 2010